A-LIST Pulse of the Community Vol 11, May 2022

The mission of the A-LIST is to use survey results to make life better for the broader Alzheimer’s andbdementia community.

Am I Repeating Myself? A Former Caregiver’s Angst about Alzheimer’s

By Meryl Comer I think most people are worried about their own risk if they have seen Alzheimer’s in their family. As a former 24-year caregiver for both my husband and mother, I worry all the time. When I walk up the steps to retrieve something and pause to try to remember what it was, I fear that I have begun to slip. When I mistakenly walk out without my house keys or misplace jewelry or money tucked away for safekeeping, I panic. Is this the beginning? Other memories are so vivid that I feel as if they happened just

Stephanie Monroe's Congressional Testimony on the Importance of Paid Leave

Stephanie Monroe, Executive Director of AfricanAmericansAgainst Alzheimer's, a network of UsAgainstAlzheimer's, testified before the Subcommittee on Health of the Committee on Energy and Commerce, "Caring for America: Legislation to Support Patients, Caregivers, and Providers." Ms. Monroe spoke about her experience as a family caregiver to her father who lives with Alzheimer's and emphasized the vital importance of health equity in driving early detection and investing in caregivers through paid family and medical leave. Watch the full testimony below.

What Will Happen to My Loved One if I Become Sick with COVID-19? Making a Plan.

By Terry Frangiosa and Meryl Comer The personal and collective fear of “What If I Get Sick with COVID-19?” continues to dominate headlines and affect the mindset of people across the nation and much of the world. To bring it closer to home and into our own (immediate and extended) families, we all feel the angst that we could potentially infect a loved one. Compounding that angst is the stress, felt by care partners of people with Alzheimer’s disease or another dementia, who balance that apprehension 24/7, even as their loved one’s dementia continues to progress. Five UsAgainstAlzheimer’s A-LIST monthly

“A Devil of a Disease”: The Current Alzheimer’s Pipeline

This article was originally published by BioSpace on August 7, 2019. By Mark Terry As anyone following Alzheimer’s research knows, drug development for the disease has been a wasteland of failed clinical trials with literally billions of dollars thrown at drugs that have proved ineffective at preventing or halting the disease. In March 2019, in what many felt was a turning point for the industry, Cambridge, Massachusetts-based Biogen and its collaboration partner, Tokyo-based Eisai, announced they were discontinuing the global Phase III clinical trials, ENGAGE and EMERGE, of aducanumab in patients with mild cognitive impairment from Alzheimer’s and mild Alzheimer’s